Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

about

Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Item

http://www.wikidata.org/entity/Q36407003

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@ast

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@en

type

Item

label

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@ast

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@en

prefLabel

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@ast

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@en

P1476

Biomarkers for the Management ...... Cancer: We Are Not There Yet.

@en

P2093

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Integrative clinical genomics of advanced prostate cancer.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

P2888

s11523-017-0500-y

P304

401-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0500-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28620691

http://www.w3.org/2001/XMLSchema#string

P921

biomarker